“We are, as Albert said in the oral remarks, doing the dose optimization for PK and formulation to select potential doses for pending data progression to Phase 3 and we expect to share that first quarter.”

In context

“mpelling shareholder value. Through our science-led transformation, we will methodically build off this base and with breakthroughs and innovation driving growth in the back half of the decade. And with that, I’d now like to turn it back over to Albert to start our Q&A. Albert Bourla: Yes. Thank you, Dave. Let’s start the Q&A session. Operator, please assemble the queue. Operator: [Operator Instructions] We’ll take our first question from Louise Chen with Cantor. Please go ahead. Louise Chen: Hi, thanks for taking my questions. So I wanted to ask you on danuglipron, when do you expect to see the actual efficacy data and if this product moves forward as anticipated, how hard would it be for you to manufacture? Albert Bourla: Mikael, you want to address it very quickly. Mikael Dolsten: Yes. We are, as Albert said in the oral remarks, doing the dose optimization for PK and formulation to select potential doses for pending data progression to Phase 3 and we expect to share that first quarter. Albert Bourla: Yes. Thank you very much. Let’s move to the next question. Operator: Our next question comes from Mohit Bansal with Wells Fargo. Mohit Bansal: Great. Thank you very much for taking my question. And just thinking about the cost guidance, cost measures here, just wanted to understand, how should we think about the margin expansion for the rest of the year. And then how should we think about it going forward in 2025 and 2026, especially as you head into the IRA territory? Albert Bourla: Perfect question for Dave. Dave Denton: Yes. So Mohit, just a couple of things. As you recall in my prepared remarks, we are focused on actually launched our manufacturing optimization program, the result of which will begin to yield results in 2025 and to generate over $1.5 billion in savings”